Učitavanje...

Glucose-lowering therapy in type 2 diabetes: New hope after the EMPA-REG outcome trial

Prevention of cardiovascular morbidity and mortality remains the key factor in the treatment of type 2 diabetes (T2DM). In the early phase of T2DM, multifactorial intervention is mandatory and glucose levels should be near normal, in particular in younger patients presenting with the highest cardiov...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Herz
Glavni autori: Schernthaner, G., Schernthaner, G.-H.
Format: Artigo
Jezik:Inglês
Izdano: Springer Medizin 2016
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4839058/
https://ncbi.nlm.nih.gov/pubmed/27071968
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00059-016-4427-3
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!